- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.03. | DIAGONAL BIO AB: Diagonal Bio publishes Year-End Report for 2024 | 1 | Cision News | ||
| DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
| 21.03. | DIAGONAL BIO AB: Diagonal Bio granted patent in Japan | 1 | Cision News | ||
| 19.03. | Nomination Committee change in Diagonal Bio AB (publ.) | 1 | Cision News | ||
| 19.03. | DIAGONAL BIO AB: Trading in Diagonal Bio's shares and warrants of series TO 2 on NGM Nordic SME begins today | 1 | Cision News | ||
| 18.03. | NGM MARKET NOTICE: #25-27 Warrants issued by Diagonal Bio AB approved for listing at NGM | 2 | Cision News | ||
| 14.03. | NGM MARKET NOTICE: #25-23 Diagonal Bio AB approved for listing at NGM | 1 | Cision News | ||
| 13.03. | DIAGONAL BIO AB: Stall Courant and Diagonal Bio agree to a pilot test of LAMPlify® | 1 | Cision News | ||
| 04.03. | Diagonal Bio AB: Diagonal Bio has been approved for delisting from Nasdaq First North Growth Market | 138 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that Nasdaq has approved Diagonal Bio's application for delisting from Nasdaq First North Growth Market ("First North"). The... ► Artikel lesen | |
| 04.03. | Diagonal Bio AB: Diagonal Bio has received conditional approval for listing on NGM Nordic SME | 146 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has received conditional approval for listing on NGM Nordic SME ("NGM"). The first day of trading is planned for 19 March 2025. This means that... ► Artikel lesen | |
| 03.03. | DIAGONAL BIO AB: Diagonal Bio applies for change of marketplace to NGM Nordic SME | 1 | Cision News | ||
| 19.02. | Diagonal Bio AB's announces last day of trading in BTU and first day of trading in warrants of series TO 2 | 2 | Cision News | ||
| 18.02. | Diagonal Bio AB resolves on a directed issue of units to all external underwriters | 4 | Cision News | ||
| 12.02. | DIAGONAL BIO AB: Diagonal Bio's CEO Karin Wehlin increases ownership | 1 | Cision News | ||
| 07.02. | Diagonal Bio AB: Diagonal Bio AB's rights issue of units oversubscribed | 295 | GlobeNewswire (Europe) | The subscription period in Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6.0 million ended on 6 February 2025 (the "Rights Issue"). The Rights... ► Artikel lesen | |
| 05.02. | DIAGONAL BIO AB: Stall Goop conducts pilot test of LAMPlify® | 1 | Cision News | ||
| 29.01. | Diagonal Bio AB: Diagonal Bio announces positive pilot test results and secures order from StallZet | 91 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of... ► Artikel lesen | |
| 23.01. | The subscription period of Diagonal Bio AB's rights issue of units commences today | 1 | Cision News | ||
| 22.01. | Diagonal Bio AB: Diagonal Bio AB publishes investment memorandum prior to upcoming rights issue of units | 175 | GlobeNewswire (Europe) | The subscription period of Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, which was resolved on 23 December 2024 by the Board of Directors together with the resolution on... ► Artikel lesen | |
| 17.01. | DIAGONAL BIO AB: Nomination Committee change in Diagonal Bio (publ.) | 2 | Cision News | ||
| 17.01. | Bulletin from the Extraordinary General Meeting of Diagonal Bio AB on 17 January 2025 | 2 | Cision News |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 6,982 | -2,19 % | Intellia Therapeutics shares up after Wolfe upgrade | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,046 | +0,97 % | Pacific Biosciences of California Aktie: Rückschlag in der Luft? | Biotech-Titel Pacific Biosciences fällt auf 52-Wochen-Tief bei schwachen Fundamentaldaten. Analysten bleiben gespalten - kann das Quartalsergebnis die Wende bringen? Die Aktie von Pacific Biosciences... ► Artikel lesen | |
| CENTOGENE | 0,101 | 0,00 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,373 | +1,97 % | ATAI Life Sciences Aktie: Bericht über jüngste Finanztrends | Das Biotechnologie-Unternehmen erforscht innovative Substanzen gegen Depressionen und entwickelt neuartige Behandlungsmethoden für psychische Erkrankungen. ATAI Life Sciences treibt die Entwicklung... ► Artikel lesen | |
| BIOMERIEUX | 113,50 | +0,09 % | BIOMERIEUX: WATCHFIRE by bioMérieux: a PCR test to detect viruses and bacteria in wastewater and respond to potential infectious disease outbreaks | ||
| CYCLACEL | 0,296 | -100,00 % | Cyclacel Pharmaceuticals, Inc. - 8-K, Current Report | ||
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,030 | +3,52 % | XTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive Officer | Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL") announced... ► Artikel lesen | |
| GENUS | 18,700 | 0,00 % | Dividendenbekanntmachungen (04.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERICAN EXPRESS COMPANY US0258161092 0,82 USD 0,742 EUR BARCLAYS PLC GB0031348658 0,055 GBP EUR BRISTOL-MYERS SQUIBB COMPANY US1101221083 0... ► Artikel lesen | |
| ABIONYX PHARMA | 1,166 | 0,00 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| ANAPTYSBIO | 18,200 | +1,11 % | AnaptysBio, Inc.: Anaptys Announces Stock Repurchase Plan | SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that... ► Artikel lesen | |
| MEIRAGTX | 5,500 | 0,00 % | MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy | As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited substantially from unilateral subretinal administration of rAAV8.hRKp.AIPL1 with improved... ► Artikel lesen | |
| AKESO | 11,500 | +9,52 % | Akeso, Inc.: Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in ... | HONG KONG, April 22, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is both pleased and honored to announce that its global first-in-class... ► Artikel lesen | |
| MAAT PHARMA | 5,860 | -1,68 % | Availability of MaaT Pharma's 2024 Universal Registration Document (URD) | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,158 | +9,20 % | Isofol (ST: ISOFOL) to receive financing to support Phase II & III trials of arfolitixorin in Japan | Isofol Medical has announced that Solasia Pharma, its development and commercialisation partner in Japan, intends to invest c SEK140m to support planned Phase II and III trials of arfolitixorin in the... ► Artikel lesen |
Das Unternehmen DIAGONAL BIO AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGONAL BIO AB finden Sie auf Wallstreet Online.
